Innovation, Commercialization, and Start-Ups in Life Sciences
Crc Press Inc (Verlag)
978-1-4822-1012-5 (ISBN)
- Lieferbar
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
The book examines how life sciences start-ups can create an exit for their investors by recognizing that a liquidity event is not consummated without due diligence. Due diligence is bigger than validating accounting transactions. It ensures the company is solving an important customer problem, demonstrating sales access, and making sure that intellectual property is impervious to competitive advancement. The due diligence process supports the telling of a compelling story to customers, investors, regulators, and acquirers.
Written by an expert who has worked with more than 200 life sciences start-ups during the past decade, the book discusses specific processes and investor milestones that must be navigated to align customer, funder, and acquirer needs. It examines these processes from the perspective of marketing value through a focus on the needs of individual constituents—investors, regulators, customers, and exit candidates. The book presents data and analytical processes articulating the fundable milestones for angel and venture capital. It gives you the tools needed to create branding for public investors and more.
Jim Jordan, a Distinguished Service Professor of Healthcare & Biotechnology Management and Senior Director of Healthcare and Biotechnology Programs at Carnegie Mellon University’s Heinz College, serves as the Chief Investment Officer of the Pittsburgh Life Sciences Greenhouse, a public-private economic and venture fund owned by Carnegie Mellon University and the University of Pittsburgh. As an accomplished Fortune 20-level executive with companies such as Boston Scientific, Johnson & Johnson and McKesson, Jim has leveraged his experience in several startup ventures and is active on multiple Boards of Directors. Through the Pittsburgh Life Sciences Greenhouse, he has applied his 25 years of experience in industry, consulting and academia to work with over 400 life science startup companies, with direct investment in 75 of them.
Part 1 – Innovation is a Process of Connected Steps. Investment Uses a Translation Process to Deliver Innovation. Investment is Critical to a Nation’s Prosperity. The Journey of Innovation Begins With Investment. The U.S. Helps Small Companies Develop Technology. Commercialization is Primarily Executed Through Two Organizational Types. Part 2 – Investment Must Be Connected to Exit. Angels and Venture Capitalists Invest in Commercialization. Create Liquidity For Your Investors. A Liquidity Event is Not Consummated Without Due Diligence. Due Diligence Reputation is a Critical Business Process. Part 3 – Align With the Industry Norms. Find the Industry Norms. Solve an Important Customer Problem. Demonstrate the Ability to Access the Sales Channel. Gather Domain-Experienced Personnel to Reduce Risk. Determine Acquirers’ Strategic Future and Purchase Triggers. Align Investor’s Fundable Milestones and Acquirer’s Exit Points. Create an IP Pyramid for Impervious Positioning. Part 4 – A Startup Must Tell a Compelling Story. Address Your Story to the Needs of All Constituencies. Deliver to Your Plan. Tell a Compelling Story With the Investor Pitch. Continuously Improve Your Message With the Plan-Do-Check-Act Cycle.
| Erscheint lt. Verlag | 20.11.2014 |
|---|---|
| Zusatzinfo | 7 Tables, black and white; 29 Illustrations, black and white |
| Verlagsort | Bosa Roca |
| Sprache | englisch |
| Maße | 156 x 234 mm |
| Gewicht | 521 g |
| Themenwelt | Schulbuch / Wörterbuch |
| Medizin / Pharmazie | |
| Technik ► Umwelttechnik / Biotechnologie | |
| Wirtschaft ► Betriebswirtschaft / Management ► Unternehmensführung / Management | |
| ISBN-10 | 1-4822-1012-6 / 1482210126 |
| ISBN-13 | 978-1-4822-1012-5 / 9781482210125 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
